Filing Details
- Accession Number:
- 0000947871-23-000777
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-07-24 16:38:29
- Reporting Period:
- 2023-07-20
- Accepted Time:
- 2023-07-24 16:38:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1764974 | Turnstone Biologics Corp. | TSBX | () | DE |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1055951 | Orbimed Advisors Llc | 601 Lexington Avenue 54Th Floor New York NY 10022 | Yes | No | Yes | No | |
1682115 | Orbimed Capital Gp Vi Llc | 601 Lexington Avenue, 54Th Floor New York NY 10022 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-07-20 | 2,682,599 | $0.00 | 2,682,599 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2023-07-20 | 416,666 | $12.00 | 3,099,265 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B-1 Preferred Stock | Disposition | 2023-07-20 | 937,372 | $0.00 | 937,372 | $0.00 |
Common Stock | Series B-2 Preferred Stock | Disposition | 2023-07-20 | 1,249,829 | $0.00 | 1,249,829 | $0.00 |
Common Stock | Series C Preferred Stock | Disposition | 2023-07-20 | 266,240 | $0.00 | 266,240 | $0.00 |
Common Stock | Series D Preferred Stock | Disposition | 2023-07-20 | 229,158 | $0.00 | 229,158 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
- These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
- Each of OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, Rishi Gupta, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.